Katherine C. Kurnit1 and Kunle Odunsi1,2 1Department of Obstetrics and Gynecology, University of Chicago, Chicago, Illinois 60637, USA 2University of Chicago Medicine Comprehensive Cancer Center, Chicago, Illinois 60637, USA Correspondence: odunsiabsd.uchicago.edu

Despite progress in other tumor types, immunotherapy is not yet part of the standard of care treatment for high-grade serous ovarian cancer patients. Although tumor infiltration by T cells is frequently observed in patients with ovarian cancer, clinical responses to immunotherapy remain low. Mechanisms for immune resistance in ovarian cancer have been explored and may provide insight into future approaches to improve response to immunotherapy agents. In this review, we discuss what is known about the immune landscape in ovarian cancer, review the available data for immunotherapy-based strategies in these patients, and provide possible future directions.